Celsion : Oral Presentation at International Vaccines Congress Entitled “Immunogenicity of DNA Vaccines based on Multicistronic Vectors and Synthetic DNA Delivery Systems” By Dr. Khursheed Anwer, Celsion's CSO

Published: 2021-10-18 07:42:11 ET CLSN

The Immunogenicity of DNA Vaccines based on Multicistronic Vectors and Synthetic Delivery Systems

International Vaccines Congress

October 18-19, 2021

New Vaccines Technologies

New approaches to safe, efficacious and rapid vaccines are warranted by:

Current vaccine strategies

DNA approach represents an attractive alternative to live attenuated and subunit vaccines

2

A Multicistronic Formulated DNA Approach to Vaccines

We are developing a next generation DNA vaccine platform that comprises:

Potential benefits of a formulated multicistronic plasmid DNA vaccine

Multiple antigens or antigen variants of SARS-CoV-2 being developed for proof-of-concept studies; comparisons will be made to marketed C-19 mRNA vaccines.

Additional pathogens to consider following the POC studies

This presentation describes the initial progress in our approach and planned future studies

3

The Multicistronic Formulated DNA Vaccines Platform

The PLACCINE Platform

Antigen DNA

Immune modifier DNA

Non-ionic polymers

Plasmid System

Delivery System

Lipopolymers

Expression

Lipopolyamines

Cross-linked polymers

Vector

PLACCINE Vaccines

Potential Administration Routes

Intramuscular

Subcutaneous

Intradermal

Inhalation

Humoral & Cell Mediated Immune Response

4

Multicistronic Vector Cassette

Antigen-1

Optimized

transcription elements

Antigen-4

Antigen-2

Antigen-3

Multicistronic Vector Cassette

5

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

Celsion Corporation published this content on 18 October 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 18 October 2021 11:41:05 UTC.